drugset / Trial / NCT01152242

Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)

NCT01152242

Phase 1 Completed 36 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether the within-subject variation in duration of action and time-action profile of glargine measured by isoglycemic clamp will be below prespecified levels.

Timeline

Start
2010-08
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator insulin glargine Protein / enzyme biologic 0.4 iu/kg

Indications